Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research Briefs: Updates From EndoGastric Solutions, Cordis, Aptus Endosystems

This article was originally published in The Gray Sheet

Executive Summary

RESPECT trial is designed to provide the kind of Level 1 evidence EndoGastic Solutions needs to persuade payers and physicians of the benefits of the EsophyX GERD-repair device. Cordis and Aptus Endosystems release new data at the Vascular Interventional Advances (VIVA) 2013 annual meeting in Las Vegas.

You may also be interested in...



Transoral GERD Devices: Riding Out The Road To Reimbursement

With health care becoming increasingly data driven, third-party payors are requiring a higher level of evidence before making a positive coverage determination for a new technology or procedure. This has made the road to reimbursement much longer and tougher for device companies in general, and manufacturers of transoral devices for GERD are a prime example.

EVAR Update: Competitors Stake Their Ground In A High-Growth Space

The endovascular abdominal aortic aneurysm repair (EVAR) market is one of the brightest growth opportunities in the medical device arena today. As a result, the competitive landscape is heating up as several new entrants stake their claim for a share of this $1+ billion opportunity.

News In Brief

Caution on robotic surgery from Ob/Gyn group. FDA gets closer to gaining access to most of fiscal 2013 user fees. More news.

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

MT032503

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel